Literature DB >> 30228641

Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.

Sarah Khan1, Roopashree Prabhushankar2, Emily Leary3, Uzma Z Khan4.   

Abstract

Differentiated Thyroid Cancer (DTC) is increasing in prevalence due to better diagnostic tools and excellent long-term survival. This study is to understand the outcome of twenty-six patients with DTC over a period of 10 years after the initial treatment with surgery and radioiodine therapy. Our study analysis showed no deaths, and indicated that older men were more likely to have persistent disease. Further studies are needed to focus on cost effective long-term management of DTC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 30228641      PMCID: PMC6140183     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  15 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 2.  Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance?

Authors:  Andrew G Gianoukakis
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

3.  Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.

Authors:  M Brassard; I Borget; A Edet-Sanson; A-L Giraudet; O Mundler; M Toubeau; F Bonichon; F Borson-Chazot; L Leenhardt; C Schvartz; C Dejax; I Brenot-Rossi; M-E Toubert; M Torlontano; E Benhamou; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2011-03-09       Impact factor: 5.958

4.  Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

Authors:  Frederik A Verburg; Bart de Keizer; Marnix G E H Lam; J M H de Klerk; Cornelis J M Lips; Inne H M Borel-Rinkes; Johannes W van Isselt
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

5.  Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members.

Authors:  Robert C Smallridge; Nancy Diehl; Victor Bernet
Journal:  Thyroid       Date:  2014-09-05       Impact factor: 6.568

6.  Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies.

Authors:  Mark M Kushnir; Alan L Rockwood; William L Roberts; Dev Abraham; Andrew N Hoofnagle; A Wayne Meikle
Journal:  Clin Chem       Date:  2013-02-08       Impact factor: 8.327

7.  Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.

Authors:  Robert W Frank; Laura Middleton; Brendan C Stack; Horace J Spencer; Ann T Riggs; Donald L Bodenner
Journal:  Head Neck       Date:  2013-06-01       Impact factor: 3.147

8.  Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome.

Authors:  Jun Soo Jeong; Hyun Ki Kim; Cho-Rok Lee; Seulkee Park; Jae Hyun Park; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

9.  Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.

Authors:  Jen-Der Lin; Chuen Hsueh; Tzu-Chieh Chao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

10.  Multistage carcinogenesis and the incidence of thyroid cancer in the US by sex, race, stage and histology.

Authors:  Rafael Meza; Joanne T Chang
Journal:  BMC Public Health       Date:  2015-08-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.